Expression of TGFBR1 and TGFBR2 in patients with Standford type A aortic dissection and its effect on prognosis

Chang Dongqing; Yeermaike·Tangshahaer; Shao Jinjie; Zhang Xiaomeng; MaiMaitiaili·Aizezi

doi:10.13498/j.cnki.chin.j.ecc.2024.04.09

Abstract：Objective To investigate the expression of Transforming Growth Factor-β Receptors(TGFBR)1 and 2 in patients with Stanford Type A Aortic Dissection(STAAD)and their impacts on prognosis.Methods 172 patients diagnosed with STAAD were included in this study who conducted at our hospital between July 2019 and May 2023.These patients were divided into a survival group(n=138)and a death group(n=34)based on their postoperative survival status.General clinical data,disease characteristics,and the expression levels of TGFBR1 and TGFBR2 in aortic wall tissues were compared between the two groups.Spearman correlation analysis and Logistic regression analysis were employed to identify potential risk factors associated with poor prognosis in STAAD patients.Furthermore,the predictive accuracy of both independent and combined risk factors was assessed using Receiver Operating Characteristic(ROC)analysis.Results The expression levels of TGFBR1 and TGFBR2 in aortic wall tissue were significantly lower in the mortality group compared to the survival group(P<0.05).Spearman correlation analysis and multivariate Logistic regression analysis indicated that cardiopulmonary bypass duration(OR=1.320,95%CI:1.021～1.626),TGFBR1(OR=0.015,95%CI:0.003～0.042),and TGFBR2 transcription levels(OR=0.031,95%CI=0.011～0.093)were potential risk factors for poor prognosis in STAAD patients.Furthermore,both independent and combined risk factors demonstrated high predictive performance for poor prognosis(P<0.05).Conclusion The expression levels of TGFBR1 and TGFBR2 in aortic wall samples from individuals with STAAD showed notable downregulation and were inversely associated with patient outcomes,which implied that TGFBR1 and TGFBR2 could serve as promising indicators for assessing and predicting the prognosis of STAAD patients in forthcoming studies.